title: Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo.
abstract: Ghrelin is a 28-amino acid peptide hormone produced predominantly in the stomach but also in a range of normal cell types and tumors, where it has endocrine, paracrine, and autocrine roles. Previously, we have demonstrated that ghrelin has proliferative and antiapoptotic effects in endometrial cancer cell lines, suggesting a potential role in promoting tumor growth. In the present study, we investigated the effect of ghrelin receptor, GHSR, and gene silencing in vitro and in vivo and characterized ghrelin and GHSR1a protein expression in human endometrial tumors. GHSR gene silencing was achieved in the Ishikawa and KLE endometrial cancer cell lines, using a lentiviral short-hairpin RNA targeting GHSR. The effects of GHSR1a knockdown were further analyzed in vivo using the Ishikawa cell line in a NOD/SCID xenograft model. Cell proliferation was reduced in cultured GHSR1a knockdown Ishikawa and KLE cells compared with scrambled controls in the absence of exogenously applied ghrelin and in response to exogenous ghrelin (1,000 nM). The tumor volumes were reduced significantly in GHSR1a knockdown Ishikawa mouse xenograft tumors compared with scrambled control tumours. Using immunohistochemistry, we demonstrated that ghrelin and GHSR1a are expressed in benign and cancerous glands in human endometrial tissue specimens, although there was no correlation between the intensity of staining and cancer grade. These data indicate that downregulation of GHSR expression significantly inhibits endometrial cancer cell line and mouse xenograft tumour growth. This is the first preclinical evidence that downregulation of GHSR may be therapeutic in endometrial cancer.
authors.affiliation: School of Biomedical Sciences, University of Queensland, St. Lucia, Queensland, Australia.
authors.forename: Jenny N T
authors.initials: JN
authors.lastname: Fung
authors.forename: Penny L
authors.initials: PL
authors.lastname: Jeffery
authors.forename: John D
authors.initials: JD
authors.lastname: Lee
authors.forename: Inge
authors.initials: I
authors.lastname: Seim
authors.forename: Deborah
authors.initials: D
authors.lastname: Roche
authors.forename: Andreas
authors.initials: A
authors.lastname: Obermair
authors.forename: Lisa K
authors.initials: LK
authors.lastname: Chopin
authors.forename: Chen
authors.initials: C
authors.lastname: Chen
mesh_terms: D000818:Animals; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000473:pathology*; D005260:Female; D005434:Flow Cytometry; D020868:Gene Silencing; D005822:Genetic Vectors; D054439:Ghrelin / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D016688:Mice, Inbred NOD; D046228:Microarray Analysis; D034741:RNA, Small Interfering / Q000494:pharmacology; D060888:Real-Time Polymerase Chain Reaction; D054440:Receptors, Ghrelin / Q000235:genetics*; D013778:Tetrazolium Salts; D013844:Thiazoles; D023041:Xenograft Model Antitumor Assays
chemical_list: D054439:Ghrelin; D034741:RNA, Small Interfering; D054440:Receptors, Ghrelin; D013778:Tetrazolium Salts; D013844:Thiazoles; C022616:thiazolyl blue
keywords: constitutive activity; endometrial cancer; ghrelin; growth hormone secretagogue receptor; mouse xenograft tumours